A Comparison of Efficacy, Safety and Cost Between MANTATM and Proglide Vascular Closure Devices Following Transfemoral Transcatheter Aortic Valve Implantation
DOI:
https://doi.org/10.17140/HROJ-8-156Keywords:
Transcatheter valve interventions, Vascular complications, Vascular closure devices (VCD)Abstract
Access site vascular complications remain a recognised complication following transcatheter aortic valve implantation (TAVI).
Suture-based vascular closure devices (VCDs) such as ProGlide® (Abbott Vascular Inc., Santa Clara, CA, USA) are widely used
in order to achieve rapid haemostasis. The MANTATM (Essential Medical Inc., Malvern, PA, USA) is a collagen plug-based VCD
which can be used as an alternative to traditional suture-based devices, but is significantly more expensive per-unit. We compare
the efficacy, safety and total cost associated with the use of the MANTATM and ProGlide® VCDs.
Methods
This retrospective study included all consecutive patients who underwent transfemoral (TF) TAVI between November 2017-June
2018. The primary endpoints were primary access site-related VARC-2 vascular complications, VARC-2 bleeding and the overall
per-patient cost incorporating treatment for complications or use of additional VCDs.
Results
A total of 136 patients were included in this study; 86 in the ProGlide® group and 50 in the MANTATM group. Baseline characteristics
of the two groups were well-matched. Three patients in the ProGlide® group required surgical repair compared to none
in the MANTATM group. However, no significant differences were observed with respect to overall primary access site-related
VARC-2 vascular complications (10.5% vs. 10%; p=0.93) or VARC-2 bleeding (9.3% vs. 4.0%; p=0.25). There was no significant
difference in the mean cost per patient when taking into consideration the use of additional VCDs and treatments for vascular
complications (£568.79 vs. £599.95; p=0.90).
Conclusion
The use of the MANTATM VCD following TF TAVI is cost-neutral compared to ProGlide® VCDs, whilst being associated with
no increase in VARC-2 vascular or bleeding complications.
Keywords
; ;.
References
Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36): 2739-2791. doi: 10.1093/eurheartj/ehx391
Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019; 380: 1695-1705. doi: 10.1056/NEJMoa1814052
Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019; 380: 1706-1715. doi: 10.1056/NEJMoa1816885
Dimitriadis Z, Scholtz W, Börgermann J, Wiemer M, Piper C, Vlachojannis M, et al. Impact of closure devices on vascular complication and mortality rates in TAVI procedures. Int J Cardiol. 2017; 241: 133-137. doi: 10.1016/j.ijcard.2017.01.088
Steinvil A, Leshem-Rubinow E, Halkin A, Abramowitz Y, Ben-Assa E, Shacham Y, et al. Vascular complications after trans-catheter aortic valve implantation and their association with mortality re-evaluated by the valve academic research consortium definitions. Am J Cardiol. 2015; 115: 100-106. doi: 10.1016/j. amjcard.2014.09.047 Ali N et al Original Research | Volume 8 | Number 1|
Toggweiler S, Leipsic J, Binder RK, Freeman M, Barbanti M, Heijmen RH, et al. Management of vascular access in transcatheter aortic valve replacement: part 2: Vascular complications. JACC Cardiovasc Interv. 2013; 6: 767-776. doi: 10.1016/j.jcin.2013.05.004
Biancari F, Romppanen H, Savontaus M, Siljander A, Mäkikallio T, Piira OP, et al. MANTA versus ProGlide vascular closure devices in transfemoral transcatheter aortic valve implantation. Int J Cardiol. 2018; 263: 29-31. doi: 10.1016/j.ijcard.2018.04.065
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61(4): 344-349. doi: 10.1016/j.jclinepi.2007.11.008
Van Mieghem NM, Latib A, van der Heyden J, van Gils L, Daemen J, Sorzano T, et al. Percutaneous plug-based arteriotomy closure device for large-bore access: A multicenter prospective study. JACC Cardiovasc Interv. 2017; 10(6): 613-619. doi: 10.1016/j. jcin.2016.12.277 Submit your article to this journal | https://openventio.org/submit-manuscript/ Original Research | Volume 8 | Number 1|
Ali N, Blackman DJ, Cunnington M, Malkin CJ. Use of the MANTA device to rescue failed pre-closure following transfemoral transcatheter aortic valve implantation. J Cardiol Cases. 2019; 19(3): 81-84. doi: 10.1016/j.jccase.2018.12.001
Gheorghe L, Brouwer J, Mathijssen H, Nijenhuis VJ, Rensing BJ, Swaans MJ, et al. Early outcomes after percutaneous closure of access site in transfemoral transcatheter valve implantation using the novel vascular closure device collagen plug-based MANTA. Am J Cardiol. 2019; 124(8): 1265-1271. doi: 10.1016/j. amjcard.2019.07.030
Moriyama N, Lindström L, Laine M. Propensity-matched comparison of vascular closure devices after transcatheter aortic valve replacement using MANTA versus ProGlide. Euro Intervention. 2019; 14(15): e1558-e1565. doi: 10.4244/EIJ-D-18-00769
Nader J, Durand E, Rodriguez C, Avinee G, Cellier G, Godin M, et al. Major vascular complications after transfemoral TAVI: incidence and impact on 30-day mortality according to VARC-1 and VARC-2 definitions. J Am Coll Cardiol. 2015, 65 (10 Supplement) A2033. Ali N et al 7
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Heart Research (HROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.